Literature DB >> 9482575

DNA deletion confined to the iduronate-2-sulfatase promoter abolishes IDS gene expression.

K M Timms1, L E Huckett, J W Belmont, S K Shapira, R A Gibbs.   

Abstract

Deficiency of the enzyme iduronate-2-sulfatase (IDS) results in Hunter syndrome, an X-linked recessive lysosomal storage disorder. In this study, analysis of a patient with features of moderate to severe Hunter syndrome identified a 178-bp deletion upstream of IDS exon 1 spanning a predicted promoter element. Sequencing of all nine IDS exons from this patient failed to identify any additional mutations within the coding regions or in intron-exon boundaries. The 178-bp deletion is flanked by two 13-bp direct repeats and potential DNA topoisomerase II recognition sites. These findings point toward nonhomologous recombination as a possible mechanism for this mutation. Expression studies on this patient do not detect any IDS transcripts, indicating that the deletion spans sequences essential for IDS expression. Complete lack of expression of IDS is consistent with the moderate to severe phenotype observed in this patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482575     DOI: 10.1002/(SICI)1098-1004(1998)11:2<121::AID-HUMU4>3.0.CO;2-M

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  3 in total

1.  Reassessment of biochemically determined Hunter syndrome carrier status by DNA testing.

Authors:  K M Timms; F J Edwards; J W Belmont; J R Yates; R A Gibbs
Journal:  J Med Genet       Date:  1998-08       Impact factor: 6.318

Review 2.  Detection of Structural Variants by NGS: Revealing Missing Alleles in Lysosomal Storage Diseases.

Authors:  Valentina La Cognata; Sebastiano Cavallaro
Journal:  Biomedicines       Date:  2022-07-29

3.  Deletion Xq27.3q28 in female patient with global developmental delays and skewed X-inactivation.

Authors:  Lauren S Marshall; Julie Simon; Tim Wood; Mei Peng; Renius Owen; Gary S Feldman; Michael V Zaragoza
Journal:  BMC Med Genet       Date:  2013-05-01       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.